KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Deferred Revenue: 2009-2022

Historic Current Deferred Revenue for Halozyme Therapeutics (HALO) over the last 14 years, with Dec 2022 value amounting to $5.5 million.

  • Halozyme Therapeutics' Current Deferred Revenue fell 54.51% to $2.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.9 million, marking a year-over-year decrease of 54.51%. This contributed to the annual value of $5.5 million for FY2022, which is 28.60% up from last year.
  • According to the latest figures from FY2022, Halozyme Therapeutics' Current Deferred Revenue is $5.5 million, which was up 28.60% from $4.3 million recorded in FY2021.
  • Halozyme Therapeutics' 5-year Current Deferred Revenue high stood at $9.3 million for FY2018, and its period low was $1.7 million during FY2020.
  • Moreover, its 3-year median value for Current Deferred Revenue was $4.3 million (2021), whereas its average is $3.8 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 84.79% in 2018, then soared by 144.90% in 2021.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Current Deferred Revenue stood at $9.3 million in 2018, then tumbled by 43.18% to $5.3 million in 2019, then slumped by 66.80% to $1.7 million in 2020, then surged by 144.90% to $4.3 million in 2021, then climbed by 28.60% to $5.5 million in 2022.